DocuSign, Inc. DOCU will release its first-quarter earnings results after the closing bell on Thursday, June 5.Analysts expect the San Francisco, California-based company to report quarterly earnings at 81 cents per share, down from 82 cents per share in the year-ago period. DocuSign projects to report quarterly revenue at $748.92 million, compared to $709.64 million a year earlier, according to data from Benzinga Pro.On April 29, Docusign named Michael Adams as new Chief Information Security Officer.DocuSi ...

CrowdStrike Holdings, Inc. CRWD shares are trading sideways on Thursday. But over the past week, the shares have been extremely volatile. Despite this, the stock demonstrated a principle of technical analysis. This is why our technical analysis team has made it our Stock of the Day.The best traders can identify important price levels in markets. These levels are called support and resistance.If a stock is trending lower, it is because there isn't enough demand to absorb all of the supply. There are more sha ...

Alvotech ALVO on Thursday collaborated with Dr. Reddy's Laboratories Ltd. RDY to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for global markets.Merck & Co Inc's MRK Keytruda (pembrolizumab) is indicated for numerous cancer types.Keytruda's worldwide sales were $29.5 billion in 2024. The collaboration combines Dr. Reddy's and Alvotech's capabilities in biosimilars, speeding up the development process and extending the global reach for this biosimilar candidate ...

Apple Inc AAPL may still be iconic, but its stock is no longer invincible. Since peaking against the Magnificent 7 in late 2022, Apple's relative performance has plunged over 45%, a jaw-dropping fall that underlines how far the tech giant has lagged behind its Big Tech peers.Chart created using TradingViewA price ratio chart comparing Apple to the aggregate Mag 7 soared to 0.17 in November 2022. Fast forward to June 2025, and that figure has collapsed to 0.09. While the broader Mag 7 group has powered ahead ...

Ride-share company Uber Technologies UBER could have a new demographic to help push its revenue growth into the future: senior citizens.Here's a look at how Uber is extending its offerings in the U.S.What Happened: While most attention on Uber now centers on autonomous vehicles and increased competition, the company is looking to expand its customer base.Many will remember the old Geico commercials that stated getting insurance was "so easy a Caveman could do it." Uber isn't catering to cavemen yet, but is ...

In February, the U.S. Food and Drug Administration (FDA) accepted Gilead Sciences, Inc.’s GILD New Drug Application (NDA) submissions for lenacapavir — the company’s twice-yearly injectable HIV-1 capsid inhibitor — for the prevention of HIV as pre-exposure prophylaxis (PrEP).What Happened: The FDA will review the applications under priority review and has assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 19, 2025.In June 2024, Gilead Sciences shared topline results from an interim ...

Rosenblatt analyst Catharine Trebnick maintained Sprinklr CXM with a Buy and a $12 price target on Thursday.Sprinklr’s results demonstrated progress and its ongoing transformation, Trebnick said. The company reported: Total revenue of $205.5 million (+5% Y/Y), beating the Street estimate of $201.8 million and coming in above guidance of $201.5 million-$202.5 million.A 4% Y/Y increase in Subscription revenue to $184.1 million, surpassing consensus estimates by $1 million and generating 90% of total revenue, ...

Apple Inc‘s AAPL latest legal setback is a headwind, but one analyst says the impact on the iPhone maker’s stock price is materially lower than investors feared. What Happened: JPMorgan analyst Samik Chatterjee has an Overweight rating on Apple, according to a Thursday research note.The note comes one day after the U.S. Court of Appeals for the Ninth Circuit denied Apple’s emergency application to halt changes to its App Store that resulted from a legal spat with Epic Games.Judge Gonzalez enforced Apple to ...

RegenXBio Inc. RGNX revealed new interim data on Thursday from the Phase 1/2 AFFINITY DUCHENNE trial.Updates include positive functional, safety, and biomarker data for RGX-202, REGENXBIO’s investigational gene therapy for Duchenne muscular dystrophy.The data update looked at five patients who were six to 12 years old when they received the gene therapy RGX-202.The functional data demonstrate consistent benefit among dose level 2 participants at 9 and 12 months following treatment with RGX-202.Also Read: Re ...

Steel tariffs are back with a bang, and investors are already positioning for the winners. As the U.S. slaps a prohibitive 50% tariff on imported steel and aluminum, Cleveland-Cliffs Inc CLF, Nucor Corp NUE and Steel Dynamics Inc STLD are emerging as the early champions of this protectionist pivot. According to Tracy Shuchart, senior economist at NinjaTrader, the tariff surge is a short-term policy maneuver, but it brings long-term opportunities for domestic producers. "At 50%, these tariffs are reaching wh ...